Arcellx

Arcellx Profit per Employee

Delisted

The Profit per Employee of Arcellx (ACLX) as of Nov 21, 2026 is -1.10 M USD. In the previous year, Profit per Employee was -513,626.79 USD — a change of 113.26% (lower).

Profit per Employee

-1.10 MUSD

YoY

113.26%

Last updated:

Profit per Employee of Arcellx is 2025 -1.10 M USD. Profit per Employee of Arcellx was 2024 -513,626.79 USD. It decreases by 113.26% lower compared to the previous year.

The Arcellx Profit per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Profit per Employee
Date
Profit per Employee
Jan 1, 2018
-39,751.20 USD
Jan 1, 2019
-85,990.43 USD
Jan 1, 2020
-153,564.59 USD
Jan 1, 2021
-305,875.60 USD
Jan 1, 2022
-902,770.33 USD
Jan 1, 2023
-338,229.67 USD
Jan 1, 2024
-513,626.79 USD
Jan 1, 2025
-1.10 M USD
The Arcellx Profit per Employee history
YEARProfit per EmployeeYoY
-1.10 MUSD+113.26%
-513,626.79USD+51.86%
-338,229.67USD-62.53%
-902,770.33USD+195.14%
-305,875.60USD+99.18%
-153,564.59USD+78.58%
-85,990.43USD+116.32%
-39,751.20USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcellx Stock analysis

What does Arcellx do? Arcellx, Inc develops innovative immunotherapies for cancer and incurable diseases, focusing on controllable cell therapies. The company's lead product CART-ddBCMA, a BCMA-targeting ddCAR therapy, is in a pivotal Phase II trial for relapsed or refractory multiple myeloma. Arcellx also advances two clinical-stage ARC-SparX programs: ACLX-001 for BCMA-targeting in multiple myeloma and ACLX-002 for CD123-targeting in acute myeloid leukemia and myelodysplastic syndrome. These therapies are developed using the company's D-Domain technology, with the goal of providing treatment options for patients with limited alternatives. Arcellx generates revenue through the development and clinical advancement of its cell therapy programs. The company's primary focus is on securing funding from strategic partnerships and clinical trial sponsorships to support its research and development activities. The key segments include patients with relapsed or refractory multiple myeloma, acute myeloid leukemia, and high-risk myelodysplastic syndrome, who are the target populations for its therapies. The company's lead program, CART-ddBCMA, is being evaluated in a pivotal Phase II trial, which is critical for advancing the therapy toward potential market approval. The firm's development pipeline includes CART-ddBCMA, ACLX-001, and ACLX-002, all leveraging the D-Domain technology for controllable cell therapies. Arcellx's business model centers on advancing these therapies through clinical trials to demonstrate efficacy and safety, with the ultimate goal of commercializing them for patients with unmet medical needs. The company's strategic partnerships and clinical trial sponsorships are essential for funding the progression of its programs from preclinical to clinical stages. Arcellx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcellx stock

Profit per Employee of Arcellx is -1.10 M USD in 2025.

Profit per Employee of Arcellx changed from -513,626.79 USD to -1.10 M USD, representing a 113.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Profit per Employee Arcellx since 2006 – with annual values, charts, and detailed analysis.

Profit per employee measures how much net income each employee generates on average. It is a key indicator of workforce efficiency.

Profit per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Profit per Employee's Arcellx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Arcellx

All Key Metrics — Arcellx